Select advances in cellular therapies in MF/SS
| Product . | Target . | Product details . | ORR . | Safety . |
|---|---|---|---|---|
| CTX13042 | CD70 | Allogeneic, CRISPR/Cas9 gene-edited anti-CD70 CAR T cell | ORR: 70% (7/10 at DL ≥3) ▪ PTCL: 80% (4/5 at DL ≥3) ▪ CTCL: 60% (3/5 at DL ≥3) | CRS: 80% ▪ Gr 1-2: 80% ▪ Gr ≥3: 0% ICANS: ▪ Gr 1-2: 30% ▪ Gr ≥3: 0% |
| CD5.CAR T-cell43 | CD5 | Autologous second- generation CD5.CAR T-cell with CD28 costimulatory domain, non–gene edited | ORR: 44% (4/9 across all DL) ▪ PTCL: 57% (4/7) ▪ CTCL: 0% (0/2) | CRS: 44% ▪ Gr 1-2: 44% ▪ Gr ≥3: 0% Neurotoxicity: 1 grade 2 neurotoxicity event that resolved with supportive care Other: severe lymphopenia (<200/µL) in 8/9 patients, median duration 16 days (range 8-27) |
| AFM13 plus NK cells43 | CD30/CD16A bispecific | First-in-class bispecific combined with preactivated, expanded cord blood-derived NK cells | Ongoing phase 2 (NCT05883449, for CHL and CD30+ PTCL) | IRR with AFM13 in ~7% (all ≤ Gr 2), no CRS, ICANS, or GVHD in prior trial (NCT04074746) |
| 5F11-28Z44 | CD30 | Anti-CD30 CAR with CD28 costimulatory domain | ORR: 43% (trial included 20 patients with CHL, 1 patient with ALCL; NCT03049449) | Trial stopped early for toxicity, including prolonged cytopenia with life-threatening sepsis, prolonged severe rashes |
| Product . | Target . | Product details . | ORR . | Safety . |
|---|---|---|---|---|
| CTX13042 | CD70 | Allogeneic, CRISPR/Cas9 gene-edited anti-CD70 CAR T cell | ORR: 70% (7/10 at DL ≥3) ▪ PTCL: 80% (4/5 at DL ≥3) ▪ CTCL: 60% (3/5 at DL ≥3) | CRS: 80% ▪ Gr 1-2: 80% ▪ Gr ≥3: 0% ICANS: ▪ Gr 1-2: 30% ▪ Gr ≥3: 0% |
| CD5.CAR T-cell43 | CD5 | Autologous second- generation CD5.CAR T-cell with CD28 costimulatory domain, non–gene edited | ORR: 44% (4/9 across all DL) ▪ PTCL: 57% (4/7) ▪ CTCL: 0% (0/2) | CRS: 44% ▪ Gr 1-2: 44% ▪ Gr ≥3: 0% Neurotoxicity: 1 grade 2 neurotoxicity event that resolved with supportive care Other: severe lymphopenia (<200/µL) in 8/9 patients, median duration 16 days (range 8-27) |
| AFM13 plus NK cells43 | CD30/CD16A bispecific | First-in-class bispecific combined with preactivated, expanded cord blood-derived NK cells | Ongoing phase 2 (NCT05883449, for CHL and CD30+ PTCL) | IRR with AFM13 in ~7% (all ≤ Gr 2), no CRS, ICANS, or GVHD in prior trial (NCT04074746) |
| 5F11-28Z44 | CD30 | Anti-CD30 CAR with CD28 costimulatory domain | ORR: 43% (trial included 20 patients with CHL, 1 patient with ALCL; NCT03049449) | Trial stopped early for toxicity, including prolonged cytopenia with life-threatening sepsis, prolonged severe rashes |
ALCL, anaplastic large cell lymphoma; CAR, chimeric antigen receptor; CHL, classical Hodgkin lymphoma; CRS, cytokine release syndrome; Gr, grade; GVHD, graft-versus-host-disease; ICANS, immune effector cell-associated neurotoxicity syndrome; IRR, infusion-related reaction; NK, natural killer; PTCL, peripheral T-cell lymphoma.